Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication

Vladimir M. Pisarev, Suk-Hee Lee, Michele C. Connelly, Arnold Fridland

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

9-(2-phosphonylmethoxyethyl)guanine (PMEG) is an acyclic nucleoside phosphonate derivative that has demonstrated significant anticancer activity in a number of in vitro and in vive animal model systems. In this study, we compared the cellular metabolism of PMEG and 9-(2- phosphonylmethoxyethyl)adenine (PMEA), a clinically active anti-HIV and antihepatitis agent, and the inhibitory activities of their putative active diphosphate derivatives, PMEGpp and PMEApp, respectively, toward human cellular DNA polymerases. PMEG was significantly more cytotoxic than PMEA against a panel of human leukemic cells. The diphosphate derivatives were the major metabolites formed in cells on both these agents, with PMEGpp reaching cellular concentration approximately 4-fold higher than that achieved for PMEApp. These differences in cellular accumulation of the diphosphate derivatives were not, however, sufficient to account for the 30-fold difference in cytotoxicity between the two analogs. PMEGpp was also at least a 7-fold more effective inhibitor of in vitro simian vacuolating virus 40 DNA replication system than that of PMEApp (IC50 = 4.6 μM). Studies with a defined primed DNA template showed that PMEGpp was a potent inhibitor of both human polymerases α and δ, two key enzymes involved in cellular DNA replication, whereas PMEApp inhibited these enzymes relatively poorly. From these studies, we can conclude that the factors that contribute to the enhanced antileukemic activity of PMEG derives both from its increased anabolic phosphorylation and the increased potency of the diphosphate derivative to target the cellular replicative DNA polymerases.

Original languageEnglish (US)
Pages (from-to)63-68
Number of pages6
JournalMolecular Pharmacology
Volume52
Issue number1
StatePublished - Jul 1997
Externally publishedYes

Fingerprint

Organophosphonates
Diphosphates
Guanine
DNA Replication
Nucleosides
DNA-Directed DNA Polymerase
Anti-HIV Agents
Simian virus 40
Enzymes
Inhibitory Concentration 50
Animal Models
Phosphorylation
9-(2-(phosphonomethoxy)ethyl)adenine diphosphate
DNA
adefovir
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pisarev, V. M., Lee, S-H., Connelly, M. C., & Fridland, A. (1997). Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Molecular Pharmacology, 52(1), 63-68.

Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. / Pisarev, Vladimir M.; Lee, Suk-Hee; Connelly, Michele C.; Fridland, Arnold.

In: Molecular Pharmacology, Vol. 52, No. 1, 07.1997, p. 63-68.

Research output: Contribution to journalArticle

Pisarev, VM, Lee, S-H, Connelly, MC & Fridland, A 1997, 'Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication', Molecular Pharmacology, vol. 52, no. 1, pp. 63-68.
Pisarev, Vladimir M. ; Lee, Suk-Hee ; Connelly, Michele C. ; Fridland, Arnold. / Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. In: Molecular Pharmacology. 1997 ; Vol. 52, No. 1. pp. 63-68.
@article{e13e022505ec4c96a25a197ea1d49b5b,
title = "Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication",
abstract = "9-(2-phosphonylmethoxyethyl)guanine (PMEG) is an acyclic nucleoside phosphonate derivative that has demonstrated significant anticancer activity in a number of in vitro and in vive animal model systems. In this study, we compared the cellular metabolism of PMEG and 9-(2- phosphonylmethoxyethyl)adenine (PMEA), a clinically active anti-HIV and antihepatitis agent, and the inhibitory activities of their putative active diphosphate derivatives, PMEGpp and PMEApp, respectively, toward human cellular DNA polymerases. PMEG was significantly more cytotoxic than PMEA against a panel of human leukemic cells. The diphosphate derivatives were the major metabolites formed in cells on both these agents, with PMEGpp reaching cellular concentration approximately 4-fold higher than that achieved for PMEApp. These differences in cellular accumulation of the diphosphate derivatives were not, however, sufficient to account for the 30-fold difference in cytotoxicity between the two analogs. PMEGpp was also at least a 7-fold more effective inhibitor of in vitro simian vacuolating virus 40 DNA replication system than that of PMEApp (IC50 = 4.6 μM). Studies with a defined primed DNA template showed that PMEGpp was a potent inhibitor of both human polymerases α and δ, two key enzymes involved in cellular DNA replication, whereas PMEApp inhibited these enzymes relatively poorly. From these studies, we can conclude that the factors that contribute to the enhanced antileukemic activity of PMEG derives both from its increased anabolic phosphorylation and the increased potency of the diphosphate derivative to target the cellular replicative DNA polymerases.",
author = "Pisarev, {Vladimir M.} and Suk-Hee Lee and Connelly, {Michele C.} and Arnold Fridland",
year = "1997",
month = "7",
language = "English (US)",
volume = "52",
pages = "63--68",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication

AU - Pisarev, Vladimir M.

AU - Lee, Suk-Hee

AU - Connelly, Michele C.

AU - Fridland, Arnold

PY - 1997/7

Y1 - 1997/7

N2 - 9-(2-phosphonylmethoxyethyl)guanine (PMEG) is an acyclic nucleoside phosphonate derivative that has demonstrated significant anticancer activity in a number of in vitro and in vive animal model systems. In this study, we compared the cellular metabolism of PMEG and 9-(2- phosphonylmethoxyethyl)adenine (PMEA), a clinically active anti-HIV and antihepatitis agent, and the inhibitory activities of their putative active diphosphate derivatives, PMEGpp and PMEApp, respectively, toward human cellular DNA polymerases. PMEG was significantly more cytotoxic than PMEA against a panel of human leukemic cells. The diphosphate derivatives were the major metabolites formed in cells on both these agents, with PMEGpp reaching cellular concentration approximately 4-fold higher than that achieved for PMEApp. These differences in cellular accumulation of the diphosphate derivatives were not, however, sufficient to account for the 30-fold difference in cytotoxicity between the two analogs. PMEGpp was also at least a 7-fold more effective inhibitor of in vitro simian vacuolating virus 40 DNA replication system than that of PMEApp (IC50 = 4.6 μM). Studies with a defined primed DNA template showed that PMEGpp was a potent inhibitor of both human polymerases α and δ, two key enzymes involved in cellular DNA replication, whereas PMEApp inhibited these enzymes relatively poorly. From these studies, we can conclude that the factors that contribute to the enhanced antileukemic activity of PMEG derives both from its increased anabolic phosphorylation and the increased potency of the diphosphate derivative to target the cellular replicative DNA polymerases.

AB - 9-(2-phosphonylmethoxyethyl)guanine (PMEG) is an acyclic nucleoside phosphonate derivative that has demonstrated significant anticancer activity in a number of in vitro and in vive animal model systems. In this study, we compared the cellular metabolism of PMEG and 9-(2- phosphonylmethoxyethyl)adenine (PMEA), a clinically active anti-HIV and antihepatitis agent, and the inhibitory activities of their putative active diphosphate derivatives, PMEGpp and PMEApp, respectively, toward human cellular DNA polymerases. PMEG was significantly more cytotoxic than PMEA against a panel of human leukemic cells. The diphosphate derivatives were the major metabolites formed in cells on both these agents, with PMEGpp reaching cellular concentration approximately 4-fold higher than that achieved for PMEApp. These differences in cellular accumulation of the diphosphate derivatives were not, however, sufficient to account for the 30-fold difference in cytotoxicity between the two analogs. PMEGpp was also at least a 7-fold more effective inhibitor of in vitro simian vacuolating virus 40 DNA replication system than that of PMEApp (IC50 = 4.6 μM). Studies with a defined primed DNA template showed that PMEGpp was a potent inhibitor of both human polymerases α and δ, two key enzymes involved in cellular DNA replication, whereas PMEApp inhibited these enzymes relatively poorly. From these studies, we can conclude that the factors that contribute to the enhanced antileukemic activity of PMEG derives both from its increased anabolic phosphorylation and the increased potency of the diphosphate derivative to target the cellular replicative DNA polymerases.

UR - http://www.scopus.com/inward/record.url?scp=0030754125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030754125&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 63

EP - 68

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 1

ER -